Recombinant Human Adenovirus Type 5 injection

DRUG4 trials

Sponsors

Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Fujian Cancer Hospital, RenJi Hospital

Conditions

Bladder (Urothelial, Transitional Cell) CancerHepatocellular CarcinomaMalignant Melanomas

Phase 1

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Fujian Cancer HospitalMalignant Melanomas

Start: 2022-10-27End: 2024-10-31Target: 10Updated: 2023-07-10

Phase 2

Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety

Not yet recruitingNCT07356791

RenJi HospitalBladder (Urothelial, Transitional Cell) Cancer

Start: 2026-02-01End: 2027-12-31Target: 18Updated: 2026-01-21

Phase 3

TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2013-01-31End: 2018-01-31Target: 266Updated: 2017-03-16

Phase 4

Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment

First Affiliated Hospital Xi'an Jiaotong UniversityHepatocellular Carcinoma

Start: 2021-12-28End: 2023-12-01Target: 66Updated: 2022-01-27